LP
APLS

LMR Partners’s Apellis Pharmaceuticals APLS Stock Holding History

LMR Partners’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-403,622
Closed -$16.2M – 1506
2026
Q1 		$16.2M Buy
+403,622
New +$8.7M 0.04% 264
2024
Q3 		– Sell
-33,900
Closed -$1.3M – 1276
2024
Q2 		$1.3M Buy
+33,900
New +$1.54M 0.01% 624
2024
Q1 		– Sell
-114,069
Closed -$6.83M – 1148
2023
Q4 		$6.83M Buy
114,069
+56,940
+100% +$2.89M 0.08% 249
2023
Q3 		$2.17M Buy
57,129
+38,693
+210% +$1.7M 0.02% 390
2023
Q2 		$1.68M Buy
+18,436
New +$1.59M 0.02% 370
2022
Q2 		– Sell
-14,219
Closed -$722K – 1284
2022
Q1 		$722K Buy
+14,219
New +$628K 0.01% 920
2021
Q4 		– Sell
-121,111
Closed -$3.99M – 1147
2021
Q3 		$3.99M Buy
+121,111
New +$6.8M 0.05% 300

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

LMR Partners's APLS Position: Q2 2026 in Review

LMR Partners sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 403,622 shares — an estimated $16.2M sold.

LMR Partners first reported a position in APLS in Q3 2021 and held it in 7 quarters. The position peaked at $16.2M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • LMR Partners reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • LMR Partners sold 403,622 Apellis Pharmaceuticals shares in Q2 2026, an estimated $16.2M.
  • LMR Partners first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • LMR Partners's Apellis Pharmaceuticals position peaked at $16.2M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.